epoetin alpha (epogen)

Erythropoiesis-Stimulating Drugs

Epoetin alfa (Epogen) Overview

  • Pharmacologic Class: Erythropoiesis-stimulating agent

  • Therapeutic Class: Hematopoietic agent

  • Mechanism of Action:

    • Stimulates erythroid progenitor cells in the bone marrow.

    • Induces erythropoiesis resulting in the release of reticulocytes.

    • Leads to increased hemoglobin and hematocrit levels.

    • Aids the body's production of red blood cells (RBCs).

    • Reduces the risk and cost associated with blood transfusions.

    • Provides significant benefit to patients with drug-associated anemia or chronic kidney disease.

Erythropoietin Production

  • Hormone Function: Erythropoietin is produced by the kidneys to stimulate RBC production (erythropoiesis).

  • Major Signal for Production: Decreased oxygen levels detected by proximal tubule cells in the kidneys.

  • Triggers for Erythropoietin Release:

    • Hemorrhage

    • Anemia

    • Chronic obstructive pulmonary disease (COPD)

    • High altitude exposure

  • Role in RBC Function:

    • Promotes hemoglobin production, essential for effective erythrocytes.

Epoetin alfa Administration and Dosage

  • Formulation: Recombinant Human Erythropoietin Injection

  • Dosage Example: Epoetin 1000 10 Injection in 0.75 ml Pre-filled Syringe (3000 IU)

  • Route of Administration: Subcutaneous and intravenous (IV) only; oral route ineffective due to digestive enzyme destruction.

  • Onset of Action: Takes 11 to 14 days to begin working.

  • Iron Requirement: Not effective without sufficient iron; patients may need to be educated on iron supplementation.

Adverse Effects of Epoetin alfa

  • Common Adverse Effect: Hypertension; gradual increase of hemoglobin can minimize this.

  • Contraindications:

    • Not recommended for patients with uncontrolled hypertension.

  • Potential Risks: Increased likelihood of myocardial infarction and stroke when aiming for hemoglobin levels > 12 g/dL.

  • Other Side Effects:

    • Nausea

    • Vomiting

    • Diarrhea

    • Arthralgias (joint pain)

Epoetin alfa Administration in Hemodialysis

  • Timing of Administration: Administer by bolus injection at the end of dialysis sessions.

  • Monitoring Therapeutic Effects: Observe for:

    • Increased RBC count, hemoglobin, and hematocrit

    • Enhanced energy and exercise capacity

    • Improved quality of life

  • Dosing Considerations:

    • Therapeutic effects vary based on dose and patient's condition.

    • Aim to achieve and maintain hemoglobin level of no more than 12 g/dL.

  • Monitoring Parameters:

    • Measure iron stores (transferrin saturation and serum ferritin) before and during treatment.

    • Monitor hemoglobin levels twice weekly until stabilized.